American Journal of Obstetrics & Gynecology
Volume 199, Issue 1 , Pages 38.e1-38.e9 , July 2008

Pregnancy complications associated with hepatitis C: data from a 2003-2005 Washington state birth cohort

Some of the data in this paper were presented at the 45th Annual Meeting of the Infectious Diseases Society of America, San Diego, CA, Oct. 4-7, 2007.

  • Steven A. Pergam, MD

      Affiliations

    • Department of Medicine, University of Washington School of Medicine, Seattle, WA
    • Corresponding Author InformationReprints: Steven A Pergam, MD, Fred Hutchinson Cancer Center, 1100 Fairview Ave. North, D3-100, P.O. Box 19024, Seattle, WA 98109.
    • ,
  • Chia C. Wang, MD, MS

      Affiliations

    • Department of Medicine, University of Washington School of Medicine, Seattle, WA
    • ,
  • Carolyn M. Gardella, MD, MPH

      Affiliations

    • Department of Obstetrics and Gynecology, University of Washington School of Medicine, Seattle, WA
    • ,
  • Taylor G. Sandison, MD, MPH

      Affiliations

    • Department of Medicine, University of Washington School of Medicine, Seattle, WA
    • ,
  • Warren T. Phipps, MD

      Affiliations

    • Department of Medicine, University of Washington School of Medicine, Seattle, WA
    • ,
  • Stephen E. Hawes, PhD

      Affiliations

    • Department of Epidemiology, University of Washington School of Medicine, Seattle, WA.

Received 15 September 2007 ,Revised 20 December 2007 ,Accepted 21 March 2008.

References 

  1. Global surveillance and control of hepatitis C (Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium). J Viral Hepat. 1999;6:35–47
  2. Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med. 1999;341:556–562
  3. Marranconi F, Fabris P, Stecca C, et al. Prevalence of anti-HCV and risk factors for hepatitis C virus infection in healthy pregnant women. Infection. 1994;22:333–337
  4. Marcellin P, Bernuau J, Martinot-Peignoux M, et al. Prevalence of hepatitis C virus infection in asymptomatic anti-HIV1 negative pregnant women and their children. Dig Dis Sci. 1993;38:2151–2155
  5. Conte D, Fraquelli M, Prati D, et al. Prevalence and clinical course of chronic hepatitis C virus (HCV) infection and rate of HCV vertical transmission in a cohort of 15,250 pregnant women. Hepatology. 2000;31:751–755
  6. Baldo V, Floreani A, Menegon T, et al. Hepatitis C virus, hepatitis B virus and human immunodeficiency virus infection in pregnant women in North-East Italy: A seroepidemiological study. Eur J Epidemiol. 2000;16:87–91
  7. Silverman NS, Jenkin BK, Wu C, et al. Hepatitis C virus in pregnancy: Seroprevalence and risk factors for infection. Am J Obstet Gynecol. 1993;169:583–587
  8. Leikin EL, Reinus JF, Schmell E, et al. Epidemiologic predictors of hepatitis C virus infection in pregnant women. Obstet Gynecol. 1994;84:529–534
  9. Goldberg D, McIntyre PG, Smith R, et al. Hepatitis C virus among high and low risk pregnant women in Dundee: Unlinked anonymous testing. BJOG. 2001;108:365–370
  10. Baeten JM, Bukusi EA, Lambe M. Pregnancy complications and outcomes among overweight and obese nulliparous women. Am J Public Health. 2001;91:436–440
  11. Burns L, Mattick RP, Cooke M. The use of record linkage to examine illicit drug use in pregnancy. Addiction. 2006;101:873–882
  12. Kennare R, Heard A, Chan A. Substance use during pregnancy: risk factors and obstetric and perinatal outcomes in South Australia. Aust N Z J Obstet Gynaecol. 2005;45:220–225
  13. Kotelchuck M. An evaluation of the Kessner Adequacy of Prenatal Care Index and a proposed Adequacy of Prenatal Care Utilization Index. Am J Public Health. 1994;84:1414–1420
  14. Lydon-Rochelle MT, Holt VL, Cardenas V, et al. The reporting of pre-existing maternal medical conditions and complications of pregnancy on birth certificates and in hospital discharge data. Am J Obstet Gynecol. 2005;193:125–134
  15. Centers for Disease Control and Prevention. BMI—body mass index: About BMI for adults. 2006 http://www.cdc.gov/nccdphp/dnpa/bmi/adult_BMI/about_adult_BMI.htmAccessed May 10, 2006
  16. Institute of Medicine, Food and Nutrition Board, Committee on Nutritional Status During Pregnancy, part I. Nutritional status and weight gain. Washington (DC): National Academy Press; 1990;
  17. Edwards LE, Hellerstedt WL, Alton IR, et al. Pregnancy complications and birth outcomes in obese and normal-weight women: Effects of gestational weight change. Obstet Gynecol. 1996;87:389–394
  18. Williams RL, Creasy RK, Cunningham GC, et al. Fetal growth and perinatal viability in California. Obstet Gynecol. 1982;59:624–632
  19. Fraser GM, Harman I, Meller N, et al. Diabetes mellitus is associated with chronic hepatitis C but not chronic hepatitis B infection. Isr J Med Sci. 1996;32:526–530
  20. Caronia S, Taylor K, Pagliaro L, et al. Further evidence for an association between non—insulin-dependent diabetes mellitus and chronic hepatitis C virus infection. Hepatology. 1999;30:1059–1063
  21. Gray H, Wreghitt T, Stratton IM, et al. High prevalence of hepatitis C infection in Afro-Caribbean patients with type 2 diabetes and abnormal liver function tests. Diabet Med. 1995;12:244–249
  22. Allison ME, Wreghitt T, Palmer CR, et al. Evidence for a link between hepatitis C virus infection and diabetes mellitus in a cirrhotic population. J Hepatol. 1994;21:1135–1139
  23. Ozyilkan E, Arslan M. Increased prevalence of diabetes mellitus in patients with chronic hepatitis C virus infection. Am J Gastroenterol. 1996;91:1480–1481
  24. Grimbert S, Valensi P, Levy-Marchal C, et al. High prevalence of diabetes mellitus in patients with chronic hepatitis C (A case-control study). Gastroenterol Clin Biol. 1996;20:544–548
  25. Mehta SH, Brancati FL, Strathdee SA, et al. Hepatitis C virus infection and incident type 2 diabetes. Hepatology. 2003;38:50–56
  26. Mehta SH, Brancati FL, Sulkowski MS, et al. Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. Ann Intern Med. 2000;133:592–599
  27. Shintani Y, Fujie H, Miyoshi H, et al. Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. Gastroenterology. 2004;126:840–848
  28. Hui JM, Sud A, Farrell GC, et al. Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression [corrected]. Gastroenterology. 2003;125:1695–1704
  29. Lonardo A, Loria P, Adinolfi LE, et al. Hepatitis C and steatosis: A reappraisal. J Viral Hepat. 2006;13:73–80
  30. Laskus T, Radkowski M, Wang LF, et al. Search for hepatitis C virus extrahepatic replication sites in patients with acquired immunodeficiency syndrome: specific detection of negative-strand viral RNA in various tissues. Hepatology. 1998;28:1398–1401
  31. Kaaja RJ, Greer IA. Manifestations of chronic disease during pregnancy. JAMA. 2005;294:2751–2757
  32. Jabeen T, Cannon B, Hogan J, et al. Pregnancy and pregnancy outcome in hepatitis C type 1b. Q J Med. 2000;93:597–601
  33. Jaffery T, Tariq N, Ayub R, et al. Frequency of hepatitis C in pregnancy and pregnancy outcome. J Coll Physicians Surg Pak. 2005;15:716–719
  34. Floreani A, Paternoster D, Zappala F, et al. Hepatitis C virus infection in pregnancy. Br J Obstet Gynaecol. 1996;103:325–329
  35. Latt NC, Spencer JD, Beeby PJ, et al. Hepatitis C in injecting drug-using women during and after pregnancy. J Gastroenterol Hepatol. 2000;15:175–181
  36. Bohman VR, Stettler RW, Little BB, et al. Seroprevalence and risk factors for hepatitis C virus antibody in pregnant women. Obstet Gynecol. 1992;80:609–613
  37. Medhat A, el-Sharkawy MM, Shaaban MM, et al. Acute viral hepatitis in pregnancy. Int J Gynaecol Obstet. 1993;40:25–31
  38. Ludlow JP, Evans SF, Hulse G. Obstetric and perinatal outcomes in pregnancies associated with illicit substance abuse. Aust N Z J Obstet Gynaecol. 2004;44:302–306
  39. Redline RW. Severe fetal placental vascular lesions in term infants with neurologic impairment. Am J Obstet Gynecol. 2005;192:452–457
  40. Sander CM, Gilliland D, Akers C, et al. Livebirths with placental hemorrhagic endovasculitis: Interlesional relationships and perinatal outcomes. Arch Pathol Lab Med. 2002;126:157–164
  41. Colon HM, Robles RR, Sahai H. The validity of drug use responses in a household survey in Puerto Rico: Comparison of survey responses of cocaine and heroin use with hair tests. Int J Epidemiol. 2001;30:1042–1049
  42. Colon HM, Robles RR, Sahai H. The validity of drug use self-reports among hard core drug users in a household survey in Puerto Rico: Comparison of survey responses of cocaine and heroin use with hair tests. Drug Alcohol Depend. 2002;67:269–279
  43. Buchan BJ, L Dennis M, Tims FM, et al. Cannabis use: Consistency and validity of self-report, on-site urine testing and laboratory testing. Addiction. 2002;97(Suppl 1):98–108
  44. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease (Centers for Disease Control and Prevention). MMWR Recomm Rep. 1998;47:1–39
  45. American College of Obstetricians and Gynecologists. Primary and preventive care: Periodic assessments (ACOG technical bulletin no. 246). Washington (DC): American College of Obstetricians and Gynecologists; 2000;p. 1-7
  46. Plunkett BA, Grobman WA. Routine hepatitis C virus screening in pregnancy: A cost-effectiveness analysis. Am J Obstet Gynecol. 2005;192:1153–1161
  47. Boaz K, Fiore AE, Schrag SJ, et al. Screening and counseling practices reported by obstetrician-gynecologists for patients with hepatitis C virus infection. Infect Dis Obstet Gynecol. 2003;11:39–44
  48. Giles ML, Sasadeusz JJ, Garland SM, et al. An audit of obstetricians' management of women potentially infected with blood-borne viruses. Med J Aust. 2004;80:328–332

 Cite this article as: Pergam SA, Wang CC, Gardella CM, et al. Pregnancy complications associated with hepatitis C: data from a 2003-2005 Washington state birth cohort. Am J Obstet Gynecol 2008;199:38.e1-38.e9.

 This study was supported by National Institute of Allergy and Infectious Diseases Grants T32 AI007044 (to S.A.P.) and AI-30731 (to C.M.G.); National Institutes of Health Grant T32 AI007140 (to W.T.P. and T.G.S.); and National Institutes of Health Grant 5 K23 AI51523 (to C.C.W.). Drs Wang and Gardella are members of the speaker's bureau for Roche and GlaxoSmithKline laboratories, respectively. Roche markets a test for hepatitis C, and GlaxoSmithKline is developing a drug intended for use in a treatment program for hepatitis C. Neither company contributed to the design, execution, review, or funding of this study.

PII: S0002-9378(08)00347-5

doi: 10.1016/j.ajog.2008.03.052

American Journal of Obstetrics & Gynecology
Volume 199, Issue 1 , Pages 38.e1-38.e9 , July 2008

Article Tools